Abeona Therapeutics, Inc.
(NASDAQ : ABEO)

( )
ABEO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
-0.92%171.792.8%$247.81m
ZTSZoetis, Inc. Class A
-0.15%85.291.9%$233.22m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
-0.52%22.942.1%$184.49m
MYLMylan N.V.
-0.31%35.533.2%$113.73m
TXMDTherapeuticsMD, Inc.
-1.42%6.6227.8%$11.56m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
1.40%29.662.0%$10.76m
ABEOAbeona Therapeutics, Inc.
1.06%14.357.9%$10.47m
TAROTaro Pharmaceutical Industries Ltd.
-0.90%112.746.3%$3.88m
KINKindred Biosciences, Inc.
0.00%12.850.3%$2.75m
LFVNLifeVantage Corporation
-5.27%9.883.3%$2.53m
PETXAratana Therapeutics, Inc.
-0.89%4.489.0%$1.21m
JAGXJaguar Animal Health, Inc.
1.77%1.150.7%$0.40m
BSPMBioStar Pharmaceuticals, Inc.
0.90%2.2411.8%$0.14m
CPHIChina Pharma Holdings, Inc.
-2.60%0.240.1%$0.03m

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX.